$1.06 1.9%
FGEN Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.


FibroGen
Price $1.06
Target Price Sign up
Volume 1,430,000
Market Cap $108M
Year Range $0.38 - $2.73
Dividend Yield 0%
Revenue per Employee $291,292
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2451M26M25M-33M-28M-0.330
Q4 '2338M5.4M32M-56M-51M-0.570
Q3 '2335M4.2M31M-64M-59M-0.520
Q2 '2341M5.7M36M-88M-85M-0.900
Q1 '2334M3.5M30M-77M-74M-0.810

Insider Transactions View All

Adib Deyaa filed to buy 82,123 shares at $1.2.
June 13 '24
Wettig Thane filed to buy 470,178 shares at $1.9.
March 11 '24
Henderson Jeffrey William filed to sell 28,866 shares at $1.
September 6 '23
Henderson Jeffrey William filed to sell 30,866 shares at $1.9.
August 8 '23
Henderson Jeffrey William filed to sell 32,866 shares at $2.7.
July 13 '23

What is the Market Cap of FibroGen?

The Market Cap of FibroGen is $108M.

How Many People Work at FibroGen?

As of our latest update, FibroGen employed approximately 566 people worldwide. However, it's important to note that FibroGen's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is FibroGen's revenue per employee?

$291,292. To calculate FibroGen's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of FibroGen?

Currently, the price of one share of FibroGen stock is $1.06.

How can I analyze the FGEN stock price chart for investment decisions?

The FGEN stock price chart above provides a comprehensive visual representation of FibroGen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling FibroGen shares. Our platform offers an up-to-date FGEN stock price chart, along with technical data analysis and alternative data insights.

Does FGEN offer dividends to its shareholders?

As of our latest update, FibroGen (FGEN) does not offer dividends to its shareholders. Investors interested in FibroGen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of FibroGen?

Some of the similar stocks of FibroGen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.